We develop new biopolymers for the treatment of respiratory conditions.
Glycocore Pharma is a start-up committed to the development of pharmaceuticals based on the active principle HYLACH®.
GLYCOCORE
Therapeutic
areas
Idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a rare chronic and progressive lung disorder with high lethality and considerable morbidity.
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a frequent disorder characterized by irreversible lung obstruction.
SARS-CoV-2 associated Acute Respiratory Distress Syndrome (ARDS)
Acute respiratory distress syndrome (ARDS) is a life-threatening condition caused by severe lung inflammation.
GLYCOCORE
Technology
Galectin-3
The Galectin family includes 15 protein members with a β-galactoside-binding domain and commonly expressed in several tissue types (Kyosov e Traber, 2012).
HYLACH
HYLACH® is a natural biopolymeric molecule composed by a hyaluronic acid chain conjugated with lactose derivative residues.
